1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,193 | 0,287 | 06.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.11. | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 47 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 19.11. | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 120 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen | |
| 22.09. | AcouSort AB: AcouSort receives new order boosting Central European collaboration | 118 | GlobeNewswire (Europe) | AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for... ► Artikel lesen | |
| 27.08. | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 92 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen | |
| 28.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 215 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen | |
| 09.04. | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 158 | GlobeNewswire (Europe) | The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of AcouSort AB (publ) (the "Company") on 9 April 2025 in Lund.
Rights issue of sharesThe EGM resolved to approve... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 226 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 26.03. | AcouSort AB: AcouSort's CEO answers questions about the company's rights issue and gives his view on the future | 236 | GlobeNewswire (Europe) | In connection with AcouSort's announcement of its plan to carry out a rights issue, several shareholders have contacted the company with questions regarding both the issue itself and how the management... ► Artikel lesen | |
| 19.03. | AcouSort AB: AcouSort in new collaboration to improve sepsis treatment | 263 | GlobeNewswire (Europe) | AcouSort's business strategy relies on early development collaborations to integrate its separation technology in partnering companies' products and systems. The most recent collaboration of this kind... ► Artikel lesen | |
| 03.03. | AcouSort AB: AcouSort and Bio-ReCell enter collaboration | 220 | GlobeNewswire (Europe) | AcouSort AB ("AcouSort") and Bio-ReCell Ltd ("Bio-ReCell") announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation... ► Artikel lesen | |
| 14.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2024 | 128 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
Fourth quarter for the GroupNet sales amounted to TSEK 1,221 (0)Result before tax amounted to... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,96 | +0,04 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,514 | -0,15 % | BioCryst Pharmaceuticals, Inc.: BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition | RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH | 213,70 | +0,23 % | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| BIOLIFE SOLUTIONS | 22,000 | +1,85 % | BioLife Solutions, Inc.: BioLife Solutions Reports Third Quarter 2025 Financial Results | Cell Processing revenue of $25.4 million, up 33% over Q3 2024
GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64%
GAAP net income of $0.6... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,850 | -1,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| CRESCENT BIOPHARMA | 10,400 | -2,80 % | Morning Market Movers: Polyrizon, Picard Medical, Crescent Biopharma, Hyster-Yale See Big Swings | OTTAWA (dpa-AFX) - At 7:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 247,99 | +30,54 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | +5,37 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | -1,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | ||
| ARCUTIS BIOTHERAPEUTICS | 31,200 | +0,13 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| NUVALENT | 109,60 | +2,56 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| QIAGEN | 40,405 | -0,02 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,75 | +1,66 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,63 | +0,13 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,710 | -4,27 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen |
ACOUSORT AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +15,49 % bei einem Aktienkurs von 0,246 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.